Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Children and Adolescents With Type 2 Diabetes
NCT07282613Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2026; status: recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07282613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282613.